This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects.

1. Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2014
This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at
various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates,
and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features
on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built
using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the
latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that
the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by
identifying new targets and MOAs to produce first-in-class and best-in-class products.
Scope
The report provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis The report reviews key pipeline products under drug profile
section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key
players involved in the therapeutics development for Non-Alcoholic Steatohepatitis and enlists all their major and minor projects The report summarizes all the
dormant and discontinued pipeline projects A review of the Non-Alcoholic Steatohepatitis products under development by companies and universities/research
institutes based on information derived from company and industry-specific sources Pipeline products coverage based on various stages of development ranging
from pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the
Non-Alcoholic Steatohepatitis pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline
products Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players
with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the
focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis Plan
mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding
Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying
prospective partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying
discontinued projects and understanding the factors that drove them from pipeline
table Of Contents
table Of Contents 2
list Of Tables 7
list Of Figures 8
introduction 9
global Markets Direct Report Coverage 9
non-alcoholic Steatohepatitis Overview 10
therapeutics Development 11
pipeline Products For Non-alcoholic Steatohepatitis Overview 11
pipeline Products For Non-alcoholic Steatohepatitis Comparative Analysis 12
non-alcoholic Steatohepatitis Therapeutics Under Development By Companies 13
non-alcoholic Steatohepatitis Therapeutics Under Investigation By Universities/institutes 16
non-alcoholic Steatohepatitis Pipeline Products Glance 17
clinical Stage Products 17
early Stage Products 18
non-alcoholic Steatohepatitis Products Under Development By Companies 19
non-alcoholic Steatohepatitis Products Under Investigation By Universities/institutes 21
non-alcoholic Steatohepatitis Companies Involved In Therapeutics Development 22
isis Pharmaceuticals, Inc. 22
daiichi Sankyo Company, Limited 23
novo Nordisk A/s 24
mochida Pharmaceutical Co., Ltd. 25
kissei Pharmaceutical Co., Ltd. 26
genfit Sa 27
orchid Chemicals & Pharmaceuticals Ltd 28
la Jolla Pharmaceutical Company 29
prometic Life Sciences Inc. 30
immuron Limited 31
phenex Pharmaceuticals Ag 32
wellstat Therapeutics Corporation 33
zafgen Inc. 34
conatus Pharmaceuticals Inc. 35
intercept Pharmaceuticals, Inc. 36
Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2014

2. obio Pharmaceutical Holdings Limited 37
tobira Therapeutics, Inc. 38
jenken Biosciences, Inc 39
kyorin Pharmaceutical Co., Ltd. 40
nasvax Ltd. 41
stelic Institute & Co. 42
galmed International Ltd. 43
connexios Life Sciences Pvt. Ltd. 44
kadmon Pharmaceuticals, Llc 45
non-alcoholic Steatohepatitis Therapeutics Assessment 46
assessment By Monotherapy Products 46
assessment By Target 47
assessment By Mechanism Of Action 50
assessment By Route Of Administration 53
assessment By Molecule Type 55
drug Profiles 57
gft-505 - Drug Profile 57
product Description 57
mechanism Of Action 57
r&d Progress 57
kd-025 - Drug Profile 59
product Description 59
mechanism Of Action 59
r&d Progress 59
obeticholic Acid - Drug Profile 60
product Description 60
mechanism Of Action 60
r&d Progress 60
liraglutide - Drug Profile 63
product Description 63
mechanism Of Action 63
r&d Progress 63
aramchol - Drug Profile 65
product Description 65
mechanism Of Action 65
r&d Progress 65
emricasan - Drug Profile 66
product Description 66
mechanism Of Action 66
r&d Progress 66
atorvastatin Calcium - Drug Profile 69
product Description 69
mechanism Of Action 69
r&d Progress 69
anti-cd3 Oral Immunotherapy - Drug Profile 70
product Description 70
mechanism Of Action 70
r&d Progress 70
imm-124e - Drug Profile 72
product Description 72
mechanism Of Action 72
r&d Progress 72
px-102 - Drug Profile 74
product Description 74
mechanism Of Action 74
r&d Progress 74
icosapent Ethyl - Drug Profile 75
product Description 75
mechanism Of Action 75
r&d Progress 75
blx-1002 - Drug Profile 76
product Description 76
mechanism Of Action 76
r&d Progress 76
tranilast - Drug Profile 78
product Description 78
mechanism Of Action 78
r&d Progress 78
Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2014

3. px-104 - Drug Profile 79
product Description 79
mechanism Of Action 79
r&d Progress 79
tipelukast - Drug Profile 81
product Description 81
mechanism Of Action 81
r&d Progress 81
gr-md-02 - Drug Profile 83
product Description 83
mechanism Of Action 83
r&d Progress 83
gcs-100 - Drug Profile 85
product Description 85
mechanism Of Action 85
r&d Progress 85
cenicriviroc - Drug Profile 87
product Description 87
mechanism Of Action 87
r&d Progress 87
pn-2xxx - Drug Profile 89
product Description 89
mechanism Of Action 89
r&d Progress 89
jkb-121 - Drug Profile 90
product Description 90
mechanism Of Action 90
r&d Progress 90
jkb-119 - Drug Profile 91
product Description 91
mechanism Of Action 91
r&d Progress 91
ak-20 - Drug Profile 92
product Description 92
mechanism Of Action 92
r&d Progress 92
pbi-4050 - Drug Profile 93
product Description 93
mechanism Of Action 93
r&d Progress 93
cnxfc-010 - Drug Profile 94
product Description 94
mechanism Of Action 94
r&d Progress 94
isis-dgat2rx - Drug Profile 95
product Description 95
mechanism Of Action 95
r&d Progress 95
zgn-839 - Drug Profile 96
product Description 96
mechanism Of Action 96
r&d Progress 96
remogliflozin Etabonate - Drug Profile 97
product Description 97
mechanism Of Action 97
r&d Progress 97
small Molecule To Inhibit Scd-1 For Nash - Drug Profile 99
product Description 99
mechanism Of Action 99
r&d Progress 99
px-103 - Drug Profile 100
product Description 100
mechanism Of Action 100
r&d Progress 100
stnm-09 - Drug Profile 101
product Description 101
mechanism Of Action 101
r&d Progress 101
Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2014

4. small Moleucles To Activate Ampk For Fatty Liver Disease - Drug Profile 102
product Description 102
mechanism Of Action 102
r&d Progress 102
non-alcoholic Steatohepatitis Recent Pipeline Updates 103
non-alcoholic Steatohepatitis Dormant Projects 133
non-alcoholic Steatohepatitis Discontinued Products 134
non-alcoholic Steatohepatitis Product Development Milestones 135
featured News & Press Releases 135
jan 14, 2014: Medicinova Announces Positive Results In Nash Mouse Model With Mn-001 And Prepares To Initiate Phase 2 Trial In The U.s. 135
jan 12, 2014: Intercept Reports Additional Details About Flint Trial Provided By Niddk 135
jan 09, 2014: Intercept Announces Nash Primary Endpoint Met: Flint Trial Stopped Early For Efficacy Based On Highly Statistically Significant Improvement In
Liver Histology 136
nov 12, 2013: Galectin Therapeutics Reports Update On Enrollment Of First Cohort Of Phase 1 Clinical Trial 137
sep 10, 2013: Galectin Therapeutics Receives Us Patent For Potential Ground-breaking Treatment For Fatty Liver Disease 138
jul 01, 2013: Galectin Therapeutics Submits Fast Track Application To Fda For Gr-md-02 In Treatment Of Fatty Liver Disease With Advanced Fibrosis 139
jun 26, 2013: Medicinova To Initiate Preclinical Trial Of Mn-001 In Non-alcoholic Steatohepatitis 139
jun 06, 2013: Cti Announces Collaboration Agreement With Galectin Therapeutics On New Phase I Clinical Trial Of Gr-md-02 For Treatment Of Non-alcoholic
Steatohepatitis 139
may 27, 2013: Genfit Announces Publication Of Data On Efficacy And Mechanism Of Action Of Gft505 In Journal Hepatology 140
apr 30, 2013: Genfit Presents Data On Gft505 At International Liver Congress Of Easl 2013 140
appendix 142
methodology 142
coverage 142
secondary Research 142
primary Research 142
expert Panel Validation 142
contact Us 143
disclaimer 143
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2014